Loading...
XASX
NX1
Market cap4mUSD
Feb 16, Last price  
0.03AUD
Name

Inhalerx Ltd

Chart & Performance

D1W1MN
XASX:NX1 chart
P/E
P/S
20.58
EPS
Div Yield, %
Shrs. gr., 5y
21.71%
Rev. gr., 5y
48.37%
Revenues
335k
-72.17%
0493,305345,78846,59997,495167,30124,8001,204,046335,097
Net income
-1m
L-11.58%
-348,364-2,095,039-1,874,856-2,272,662-1,011,342-1,111,129-1,896,605-1,443,271-1,276,087
CFO
-369k
L-81.20%
-229,025-2,560,365-2,064,465-1,866,184-1,085,769-1,161,707-1,846,299-1,961,860-368,767

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 2016 and headquartered in Sydney, Australia, InhaleRx Limited is an Australian company primarily engaged in advancing and bringing to market medical drug delivery systems. The firm also dedicates efforts to developing specialized inhaled drug formulations. A notable product within its portfolio is the Medihale inhaler, a distinctive sealed-pod device engineered for compatibility with its inhaled medications. This entity formerly traded as Lifespot Health Ltd, officially adopting the name InhaleRx Limited in October 2021.
IPO date
Jan 11, 2017
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT